CURE

FDA Approves PD-L1 Test to Guide Keytruda Use in Esophageal and GEJ Cancer

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit ...

Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?

Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Fierce Biotech

Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...
pharmaphorum

Keytruda cleared for NHS use in early head and neck cancer

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...

Merck announces another pricy purchase ahead of Keytruda deadline

Merck headquarters in Rahway, NJ. RAHWAY, N.J. - Merck is spending $6.7 billion to bolster its cancer drug portfolio. That's ...
FiercePharma

Merck's Keytruda bounces back from pair of trial flops with ⁠interim win in earlier lung cancer

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two ...
CURE

Expert Explains Keytruda Combo Survival Gains in Resistant Ovarian Cancer

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves ...
Stocktwits on MSN

SLS vs. TERN: Which pharma stock has more upside as Merck eyes $6B cancer bet ahead of Keytruda patent cliff

SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance ...